Drug updated on 12/11/2024
| Dosage Form | Tablet (oral: 60 mg, 100 mg, 150 mg) |
| Drug Class | Tetracycline-class drugs |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1]
- Sarecycline (Seysara) has demonstrated efficacy in treating both facial and truncal acne and is conditionally recommended for acne management, although it is not considered first-line treatment based on the evidence provided.
- In comparative effectiveness, all oral tetracyclines, including doxycycline and minocycline, are noted to be variably effective against facial acne, while sarecycline specifically shows efficacy in treating truncal acne, distinguishing it from other tetracyclines.
- The reviewed studies included a total of 226,019 pediatric and adult acne patients, but specific effectiveness outcomes across these groups were not detailed in the studies.
- No safety information is available in the reviewed studies.
- The reviewed studies included a total of 226,019 pediatric and adult acne patients, but there is no population type or subgroup information available in the studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Seysara (sarecycline) Prescribing Information. | 2023 | Almirall, LLC, Malvern, PA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Oral Tetracyclines and Acne: A Systematic Review for Dermatologists | 2020 | Journal of Drugs in Dermatology |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Guidelines of care for the management of acne vulgaris | 2024 | Journal of the American Academy of Dermatology |